Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease.
1. What is known about the role of inflammation in the pathogenesis of Parkinson’s disease (PD)? (0:06)
2. What is the rationale for the use of mesenchymal stem cells as immunomodulatory therapy in people with PD? (2:04)
See also the 2nd part of this interview here.
Disclosures: Prof. Mya Schiess is the principal investigator of the study discussed in this video interview, which was sponsored by philanthropic support to the Regenerative Movement Disorders Fund and conducted at The University of Texas Health Science Center, Houston, TX, USA.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
Share this Video
Related Videos In Parkinson's Disease
Prof. K Ray Chaudhuri: Sleep Issues in Parkinson’s Disease – Diagnosis, Intervention & Practical Advice
In conjunction with the European Parkinson’s Disease Association (EPDA), we had the pleasure of meeting with Prof. K Ray Chaudhuri to discuss sleep issues among people with Parkinson’s Disease. The discussion highlights the appropriate diagnosis of sleep disorders, intervention strategies, practical advice for healthcare professionals, patients and caregivers, and the impact of sleep issues on […]
Raul Martinez-Fernandez, AAN 2021: Focused Ultrasound Subthalamotomy for Parkinson’s Disease
TouchNEUROLOGY met with Raul Martinez-Fernandez (University Hospital HM Puerta del Sur, Móstoles, Spain) to discuss the recent trial investigating focused ultrasound subthalamotomy and it’s role in the management of Parkinson’s Disease. The abstract entitled: ‘Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!